Some caveats for outcome adaptive randomization in clinical trials

Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects

Volumn , Issue , 2015, Pages 287-305

  Thall, Peter F ^a   Fox, Patricia S ^a   Wathen, J Kyle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL APPLICATIONS; RANDOM PROCESSES;

BAYESIAN FRAMEWORKS; CLINICAL TRIAL; OPTIMAL ACTIONS; OPTIMALITY CRITERIA; SAMPLE SIZES; SEQUENTIAL DECISIONS; SURVIVAL TIME; UNBIASED ESTIMATOR;

PATIENT TREATMENT;

EID: 85031691961     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18640     Document Type: Chapter

References (26)

1. Austin, P. C. (2010). The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Statistics in Medicine 29, 2137-2148.
2. Azriel, D., Mandel, M., Rinott, Y. (2011). The treatment versus experiment dilemma in dose-finding studies. Journal of Statistical Planning and Inference 141, 2759-2768.
3. Berry, D. A., Eick, S. G. (1995). Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Statistics in Medicine 14, 231-246.
4. Braun, T. M. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Contemporary Clinical Trials 23, 240-256.
5. Carlin, B. P., Zhong, W., Koopmeiners, J. S. (2013). Discussion of \Smallsample behavior of novel phase I cancer trial designs” by Assaf P. Oron and Peter D. Hoff. Clinical Trials 10, 81-85.
6. Cheung, Y. K. (2011). Dose Finding by the Continual Reassessment Method. Chapman & Hall/CRC Biostatistics Series, Boca Raton, FL.
7. Cornfield, J., Halperin, M., Greenhouse, S. W. (1969). An adaptive procedure for sequential clinical trials. Journal of the American Statistical Association 64, 759-770.
8. Hernan, M. A., Brumback, B., Robins, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 5, 561-570.
9. Hu F., Rosenberger, W. F. (2006). The Theory of Response-Adaptive Randomization in Clinical Trials. Wiley, New York.
10. Jennison, C., Turnbull, B. W. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC Interdisciplinary Statistics, Boca Raton, FL.
11. Karrison, T. G., Huo, D., Chappell, R. (2003). A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials 24, 506-522.
12. Korn, E. L., Freidlin, B. (2011). Outcome-adaptive randomization: Is it useful? Journal of Clinical Oncology 29, 771-776.
13. Lee, J. J., Chen, N., Yin, G. (2012). Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clinical Cancer Research 18, 4498-4507.
14. Maki, R. G., Wathen, J. K., Hensley, M. L., Patel, S. R., Priebat, D. A., Okuno, S., Samuels, B., Fanucchi, M., Harmon, D., Schuetze, S. M., Reinke, D., Thall, P. F., Benjamin, R. S., Baker, L. H. (2007). An adaptively randomized phase III study of gemcitabine and docetaxel versus gemcitabine alone in patients with metastatic soft tissue sarcomas. Journal of Clinical Oncology 25, 2755-1763.
15. Moodie, E. E. M., Richardson, T. S., Stephens, D. A. (2007). Demystifying optimal dynamic treatment regimes. Biometrics 63(2), 447-455.
16. O’Quigley, J., Pepe, M., Fisher, L. D. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46, 33-48.
17. Oron, A. P., Hoff, P. D. (2013). Small-sample behavior of novel phase I cancer trial designs. Clinical Trials 10, 63-80.
18. Robins, J. M. (1994). Correcting for non-compliance in randomized trials using structural nested mean models. Communications in Statistics- Theory and Methods 23, 2379-2412.
19. Sutton, R. S., Barto, A. G. (1998). Reinforcement Learning: An Introduction. Cambridge, MA: MIT Press.
20. Thall, P. F., Cook, J. D. (2004). Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693.
21. Thall, P. F., Nguyen, H. Q. (2012). Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. Journal of Biopharmaceutical Statistics 22, 785-801.
22. Thall, P. F., Nguyen, H. Q., Braun, T. M., Qazilbash, M. (2013). Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 69, 673-682.
23. Thall, P. F., Wathen, J. K. (2005). Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine 24, 1947-1964.
24. Thall, P. F., Wathen, J. K. (2007). Practical Bayesian adaptive randomization in clinical trials. European Journal of Cancer 43, 860-867.
25. Thompson, W. R. (1933). On the likelihood that one unknown probability exceeds another in view of the evidence of the two samples. Biometrika 25, 285-294.
26. Yuan, Y., Yin, G. (2011). On the usefulness of outcome-adaptive randomization. Journal of Clinical Oncology 29, 390-392.